ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lilly’s CGRP Emgality and Spark’s Luxturna win CHMP backing, as Sarepta’s Exondys misses
September 25, 2018The European Medicines Agency’s (EMA) drug review panel is on fire this week. It recommended 13 medicines—including Eli Lilly’s CGRP player Emgality—for approval, nixed Sarepta’s controversial Duchenne ... -
FDA Approves Ajovy
September 18, 2018The US Food and Drug Administration (FDA) has approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults... -
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention
September 18, 2018US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults. -
Amgen, Novartis’ migraine therapy impresses again
July 16, 2018Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated. -
Allergan’s experimental migraine drug hits trial targets
July 10, 2018Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine. -
Teva and Alder sign global licence agreement on anti-CGRP therapy
January 11, 2018Teva Pharmaceuticals International has entered a global licence agreement with Alder BioPharmaceuticals for anti-calcitonin gene-related peptide (CGRP) antibodies and their usage techniques.
Pharma Sources Insight January 2025
